Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Deferred Taxes (2023 - 2025)

Iovance Biotherapeutics has reported Deferred Taxes over the past 3 years, most recently at $184000.0 for Q4 2025.

  • Quarterly results put Deferred Taxes at $184000.0 for Q4 2025, down 88.2% from a year ago — trailing twelve months through Dec 2025 was -$2.1 million (up 26.77% YoY), and the annual figure for FY2025 was -$2.1 million, up 26.77%.
  • Deferred Taxes for Q4 2025 was $184000.0 at Iovance Biotherapeutics, up from -$2.4 million in the prior quarter.
  • Over the last five years, Deferred Taxes for IOVA hit a ceiling of $2.0 million in Q2 2025 and a floor of -$2.4 million in Q3 2025.
  • Median Deferred Taxes over the past 3 years was -$1.4 million (2024), compared with a mean of -$761636.4.
  • Biggest five-year swings in Deferred Taxes: plummeted 205.66% in 2024 and later soared 236.35% in 2025.
  • Iovance Biotherapeutics' Deferred Taxes stood at -$1.8 million in 2023, then skyrocketed by 188.63% to $1.6 million in 2024, then plummeted by 88.2% to $184000.0 in 2025.
  • The last three reported values for Deferred Taxes were $184000.0 (Q4 2025), -$2.4 million (Q3 2025), and $2.0 million (Q2 2025) per Business Quant data.